2021

1. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

   Cancer Medicine, Vol. 10, Núm. 4, pp. 1314-1326